US Patent 9,669,009: Scope, Claim Architecture, and US Landscape for Rapidly Dispersible Levetiracetam in a Bound Porous Matrix
US Patent 9,669,009 is a therapeutic-method patent built around a specific formulation-and-performance envelope for levetiracetam (LEV) delivered as a rapidly dispersible solid dosage form made from a bound porous matrix. The independent claims are drafted as methods of treating a levetiracetam-responsive disease, condition, or disorder, but the operative limitations are formulation, device attributes (hardness, porous/non-compressed traits, external vs internal hardness), and pharmacokinetic (PK) performance metrics (Cmax, Tmax, and AUC ranges under fasted and fed dosing, plus fed/fasted ratios).
The claim set also embeds multiple manufacturing and characterization constraints (disintegrant and binder wt ranges, moisture limits, oxidative degradant limits, dissolution/dispersion timing in specified apparatus/media, porosity and printed-layer structure, and option sets for surfactants/antioxidants/glycerin).
What is the core invention scope in claim 1?
Independent claim 1 (fasted PK and dispersion target)
Claim 1 recites a method of treating a therapeutically responsive condition by orally administering (one or more times daily) a subject a dosage form that meets all of the following core elements:
1) Dosage form type and dispersion performance
- “rapidly dispersible solid dosage form”
- LEV in a “bound porous matrix”
- Matrix disperses in about 15 sec or less in about 15 mL or less of water or saliva
2) Hardness
- Matrix has hardness of at least 2 kp
3) Composition by weight
- LEV: 50-80% wt
- At least one disintegrant: 3-35% wt
- At least one binder: 0.5-20% wt
4) PK constraints in the fasting state
Claim 1 locks in Cmax ranges by dose when administered in the fasting state:
| Dose (mg) |
Cmax range (micrograms/mL) |
| 1000 |
13-53 |
| 750 |
9-37 |
| 500 |
5-20 |
| 250 |
4-7 |
These Cmax ranges are a central scoping element because they are not generic. They define a performance window that a design-around must defeat.
5) Therapeutic framing
- The claim is a treatment method for diseases/conditions responsive to LEV, but the functional differentiators are the product attributes above.
Claim 2 and 3: additional PK tightening
- Claim 2: adds Tmax range 0.15-1.5 hours.
- Claim 3: adds AUC windows (AUC0-t and/or AUCinf), by dose:
| Dose (mg) |
AUC0-t (microg-hr/mL) |
AUCinf (microg-hr/mL) |
| 1000 |
170-397 |
176-410 |
| 750 |
135-315 |
140-324 |
| 500 |
90-209 |
93-216 |
| 250 |
54-127 |
56-131 |
Claim 4: equivalence to KEPPRA® tablet (NDA N021035)
- Claim 4: dosage form is equivalent to KEPPRA® tablet (NDA No. N021035) on an equi-dose basis in terms of Cmax and AUC metrics (Cmax, AUC0-t and/or AUCinf).
This adds an additional interpretive layer: even though Claim 1 already constrains Cmax/AUC ranges, Claim 4 ties the formulation to an industry reference benchmark.
Claims 5-8: dosing frequency and food effect fingerprint
- Claim 5: 1 to 3 times daily, and Cmax is determined with respect to single dose.
- Claim 6: adds fed/fasted ratio fingerprint:
- Cmax fed/fasted = 0.55 to 0.74
- Tmax fed/fasted = 5 to 21 hours
- Claim 7: adds AUC fed/fasted ratios:
- AUC0-t ratio = 0.89 to 0.98
- AUCinf ratio = 0.89 to 0.99
- Claim 8: adds a multi-part limitation set about physical attributes, dispersion/dissolution hierarchy, LEV form, moisture, hardness uniformity, and optional add-ins.
What does claim 8 lock down (design-critical product constraints)?
Claim 8 depends from claim 1 and introduces a long, conjunctive set of constraints, including negative and conditional features that narrow the permitted dosage form architecture.
Key constraints in claim 8 (selected high-impact elements):
- Not compressed:
- dosage form is not compressed
- matrix is not compressed
- Hardness gradient:
- exterior harder than interior
- Dispersion vs dissolution timing hierarchy:
- dissolution time of LEV is slower than dispersion time of matrix
- Dispersion timing in small volume:
- matrix disperses in about 10 seconds or less in aqueous fluid
- LEV dissolution extent by time:
- at least 75% (or 90% or 95%) of LEV dissolves in about 2 minutes or less
- LEV physical/chemical form options:
- hydrate, hemi-hydrate, crystalline, amorphous, anhydrate, or combinations
- Moisture limit:
- not more than 10% wt and not less than 0.1% moisture (loss on drying at 120°C)
- Hardness uniformity:
- hardness of the matrix is substantially uniform
- Optional additional medicaments
- Glycerin inclusion options:
- glycerin included, and if so, content 0.05%-3%
- USP dissolution apparatus constraint:
- at least 95% LEV dissolved in 5 minutes or less in 900 mL aqueous media at pH 1.2, 4.5, or 6.8
- USP paddle apparatus at 50 RPM
Any candidate infringement analysis must check each of these limitations if claim 8 (or claims depending from claim 8) are asserted.
How broad is the “option-set” coverage around excipients and additives?
Claims 9-13 and 10-12 add layered coverage around excipient families and specific wt bands.
Claim 9 and 10: surfactants/antioxidants and excipient ranges
- Claim 9: matrix further comprises one or more surfactants and one or more antioxidants, and optionally includes glycerin, glidants, flavorants, preservatives.
- Claim 10: quantifies ranges (wt based on final dosage form):
- surfactant: 0.05-1%
- antioxidant: 0.005-5.0%
- binder: 5-15%
- disintegrant: 10-30%
- glidant: 0.1-2.0%
- matrix mass options: 250-1000 mg LEV dose corresponds to specific embodiments (250/500/750/1000 mg)
Claim 11: hardness range and printed incremental layer architecture
Claim 11 tightens mechanical/structural details:
- hardness: 2-10 kp, or narrower ranges (2-6 kp, or 3-9 kp)
- matrix disperses in 10 sec or less in 15 mL
- printed incremental layer architecture:
- matrix comprises 15 to 50 (or 25 to 50) printed incremental layers
- layer thickness 0.008 to 0.012 inches
- porous and non-compressed or combinations
Claim 12 and 13: specific ingredient table and stability
- Claim 12: example ingredient wt % bands:
- LEV 60-70%
- disintegrant 20-25%
- binder 10-15%
- sweetener 0.5-2%
- glidant 0.1-1.5%
- glycerin 0.1-5%
- surfactant 0.05-1.5%
- flavor 0-0.5%
- Claim 13: oxidative degradant:
- ≤0.1% oxidative degradant after storage at 21°C for 6 months at 75% RH
What are the “fed” variants in claims 15-20?
The patent includes a second independent-method pathway parallel to claim 1, but using fed-state PK metrics.
Independent claim 15
Adds/changes:
- Cmax ranges in the fed state (fasted-to-fed shift)
- Tmax range and AUC ranges are fed-based
- Retains composition and dispersion/hardness requirements:
- bound porous matrix disperses in ≤15 sec in ≤15 mL
- hardness ≥2 kp
- composition wt ranges identical to claim 1 (LEV 50-80%, disintegrant 3-35%, binder 0.5-20%)
Cmax ranges in fed state:
| Dose (mg) |
Cmax range (micrograms/mL) |
| 1000 |
14-27 |
| 750 |
10-19 |
| 500 |
5-10 |
| 250 |
4-73 |
Claim 15 also includes fed-state Cmax but the 250 mg line appears as 4-73 in the provided text; whether it is a transcription issue or a true upper bound, it functions as written in the claim language you supplied.
Claim 16 and 17: fed Tmax/AUC ranges
- Claim 16: Tmax 2-5 hours
- Claim 17: AUC ranges (AUC0-t, AUCinf):
| Dose (mg) |
AUC0-t (microg-hr/mL) |
AUCinf (microg-hr/mL) |
| 1000 |
183-342 |
190-355 |
| 750 |
145-271 |
150-282 |
| 500 |
96-180 |
100-187 |
| 250 |
58-109 |
60-113 |
Claims 18-20
- Claim 18: equivalence to KEPPRA® tablet (NDA N021035) on equi-dose basis for Cmax/AUC metrics
- Claim 19: dosing frequency 1 to 3 times daily, single-dose Cmax measurement
- Claim 20: repeats the claim 8-type physical/product constraints with “not compressed,” exterior harder than interior, dispersion/dissolution hierarchy, LEV form options, moisture, hardness uniformity, glycerin option set, and USP dissolution criteria.
How does claim 29 expand scope to a 3D-printed matrix?
Claim 29 recasts the matrix as three-dimensionally printed and keeps the same performance thresholds:
- 3D printed rapidly dispersible solid bound matrix
- LEV 50-80%
- disintegrant 3-35%
- binder 0.5-20%
- disperses ≤15 sec in ≤15 mL
- hardness ≥2 kp
Claim 30 further adds:
- porous and non-compressed
- water-soluble binder
- antioxidants 0.005-5.0%
- LEV 250-1000 mg
- moisture: ≤10% wt and ≥0.1%
- disperses ≤15 sec in ≤15 mL
- hardness ≥2 kp
This is important because it ties the claimed architecture to a manufacturing method category (3D printing) while retaining the product behavior constraints.
What are the strongest “infringement tripwires” to test first?
From a landscape and enforcement perspective, the highest value limitations are those that are (a) quantitative, (b) specific to fasted/fed PK, and (c) structurally linked to dispersion/dissolution and mechanical strength. The claim set makes those the gatekeepers.
Tripwire checklist (quantitative)
- Dispersion speed: disperses ≤15 sec in ≤15 mL water/saliva (and in some dependent claims, ≤10 sec)
- Hardness: ≥2 kp (and optionally 2-10 kp, 2-6 kp, 3-9 kp)
- Composition:
- LEV 50-80%
- disintegrant 3-35%
- binder 0.5-20%
- PK windows by dose in fasted state (claim 1) and fed state (claim 15)
- Tmax constraints (claim 2 or claim 16)
- AUC windows (claim 3 or claim 17)
- Food effect ratios (claims 6-7)
- Moisture: 0.1% to 10% (loss on drying at 120°C)
- USP dissolution: at least 95% LEV dissolved in ≤5 minutes in 900 mL at pH 1.2/4.5/6.8, paddle 50 RPM
- Mechanical build (in claim 11): incremental printed layers and thickness
- 3D printing (claim 29-30)
US patent landscape implications (practical scope boundaries)
1) This is a formulation/PK-focused “method-of-use” patent
Even though claim language is “method of treating,” the enforceable subject matter is a dosage form that must meet stringent dispersion, hardness, composition, and PK endpoints. Generic developers cannot rely on mere equivalence in active ingredient alone.
2) Design-around pressure concentrates around PK and dispersion-hardness parity
Because multiple dependent claims lock in:
- fasted Cmax and AUC windows
- fed Cmax and AUC windows
- fed/fasted ratios
- dispersion speed and mechanical hardness traits
a competitor product would need to move outside the numeric PK envelope while also avoiding the structural and physical limitations (especially “not compressed,” porous/non-compressed constraints in dependent claims).
3) “Equivalence to KEPPRA® tablet” raises alignment risk
Claims 4 and 18 add an explicit comparative reference to KEPPRA® tablet under NDA N021035 on an equi-dose basis. That clause can act as a broad claim interpretation hook for comparative PK alignment if a product ends up close to reference exposure profiles.
4) Dissolution test stringency is unusual for oral solid PK claims
The USP paddle dissolution criteria (pH 1.2/4.5/6.8; 900 mL; 50 RPM; ≥95% in ≤5 min) is a tight process-performance coupling, increasing the likelihood that formulation changes to alter PK also change dissolution behavior and dispersion hierarchy.
Claim-by-claim scope map (what each layer adds)
Independent anchors
- Claim 1: fasted Cmax windows + dispersion ≤15 sec/≤15 mL + hardness ≥2 kp + composition wt ranges
- Claim 15: fed Cmax windows + dispersion ≤15 sec/≤15 mL + hardness ≥2 kp + same composition ranges
Core PK add-ons
- Claim 2: fasted Tmax 0.15-1.5 h
- Claim 3: fasted AUC0-t/AUCinf windows
- Claim 16: fed Tmax 2-5 h
- Claim 17: fed AUC windows
Comparator anchor
- Claim 4: equi-dose equivalence to KEPPRA® tablet (N021035) for Cmax/AUC metrics
- Claim 18: same but for fed-state Cmax/AUC metrics
Food effect
- Claim 6-7: fed/fasted ratios for Cmax and AUC
Physical/product architecture
- Claim 8 / Claim 20: not compressed; exterior harder than interior; dispersion/dissolution hierarchy; matrix dispersion ≤10 sec; LEV dissolution extent; LEV form; moisture; hardness uniformity; glycerin option; USP dissolution requirement
Excipients and stability
- Claims 9-10, 12, 13: surfactant/antioxidant/glycerin/glidant/sweetener and wt ranges; oxidative degradant threshold
3D printing structure
- Claim 11: printed incremental layers and layer thickness
- Claim 29-30: 3D-printed bound porous matrix, water-soluble binder, antioxidant band, moisture range, and retained performance
Key Takeaways
- US 9,669,009 claims a specific oral LEV solid: a bound porous matrix that disperses in ≤15 sec in ≤15 mL, with hardness ≥2 kp, and a defined LEV/disintegrant/binder wt envelope.
- The patent’s practical scope is governed by numeric PK targets:
- fasted Cmax (claim 1), Tmax (claim 2), and AUC (claim 3)
- fed Cmax (claim 15), Tmax (claim 16), and AUC (claim 17)
- plus fed/fasted ratios (claims 6-7).
- Dependent claims add formulation architecture and process-performance constraints that function as enforcement tripwires: not compressed, exterior harder than interior, moisture 0.1%-10%, and USP paddle dissolution (≥95% in ≤5 min across pH 1.2/4.5/6.8 at 50 RPM).
- 3D printing is captured in claim 29-30 (and layer structure in claim 11), expanding scope to printed porous/non-compressed architectures while keeping the same dispersion and mechanical targets.
- “Equivalent to KEPPRA® tablet (NDA N021035)” in claims 4 and 18 creates a reference-aligned boundary that can increase infringement risk for products that match KEPPRA® exposure on an equi-dose basis.
FAQs
1) Is US 9,669,009 a composition patent or a method-of-use patent?
It is drafted as a method of treating (treatment method claims) but is enforced through stringent product-formulation and PK performance limitations tied to the administered dosage form.
2) What single limitation most directly constrains design-arounds?
Fasted/fed Cmax and AUC numeric ranges tied to dose plus the dispersion and hardness requirements, especially when combined in dependent claim chains.
3) Does the patent require 3D printing?
Not in the main independent claim 1 or 15, but it is explicitly claimed in claim 29-30, and printed-layer structure is included in claim 11.
4) Are “not compressed” limitations always required?
They appear in dependent claims (notably claim 8 and claim 20). If those dependent claims are asserted, the product must satisfy those negative/structural requirements.
5) Does the patent include dissolution testing requirements?
Yes. Claim 8 and claim 20 require ≥95% LEV dissolved in ≤5 minutes in a 900 mL USP paddle apparatus at 50 RPM across specified pH media.
References (APA)
[1] United States Patent No. 9,669,009. (n.d.). “Method of treating a disease, condition or disorder that is therapeutically responsive to levetiracetam using a rapidly dispersible solid dosage form comprising levetiracetam in a bound porous matrix.”
